Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Migraine treatment outcomes with rizatriptan in triptan-naive patients: A naturalistic study
Autore:
Solomon, S; Frishberg, B; Hu, XH; Markson, L; Berger, M;
Indirizzi:
Merck & Co Inc, Outcomes Res & Management, W Point, PA 19486 USA Merck & Co Inc W Point PA USA 19486 s & Management, W Point, PA 19486 USA Neurol Ctr, La Jolla, CA USA Neurol Ctr La Jolla CA USANeurol Ctr, La Jolla, CA USA Montefiore Med Ctr, New York, NY USA Montefiore Med Ctr New York NY USAMontefiore Med Ctr, New York, NY USA
Titolo Testata:
CLINICAL THERAPEUTICS
fascicolo: 6, volume: 23, anno: 2001,
pagine: 886 - 900
SICI:
0149-2918(200106)23:6<886:MTOWRI>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
UNITED-STATES; 10 MG; LONG-TERM; 2.5 MG; ZOLMITRIPTAN; MANAGEMENT; EPIDEMIOLOGY; SUMATRIPTAN; HEADACHE; RELIEF;
Keywords:
migraine; triptans; rizatriptan; naturalistic study;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
24
Recensione:
Indirizzi per estratti:
Indirizzo: Hu, XH Merck & Co Inc, Outcomes Res & Management, POB 4,WP39-164, W Point,PA 19486 USA Merck & Co Inc POB 4,WP39-164 W Point PA USA 19486 nt, PA 19486 USA
Citazione:
S. Solomon et al., "Migraine treatment outcomes with rizatriptan in triptan-naive patients: A naturalistic study", CLIN THER, 23(6), 2001, pp. 886-900

Abstract

Background: The 5-hydroxytryptamine(1B/1D), agonists, or triptans, are thenewest class of drugs to become available for the acute treatment of migraine. The class currently includes sumatriptan, zolmitriptan, naratriptan, and rizatriptan. The efficacy of rizatriptan in the acute treatment of migraine has been established against placebo and other oral triptans in controlled comparative trials. Objective: The US Migraine Assessment Protocol (USMAP) collected data on the use of rizatriptan in a naturalistic setting reflecting clinical practice, This paper presents results for patients enrolled in the USMAP study whohad never taken a triptan before the study. Methods: At enrollment, 216 patients completed a questionnaire describing their responses to their current nontriptan medications. They were then given specially packaged samples of 4 standard 10-mg rizatriptan tablets and 4orally disintegrating 10-mg, rizatriptan tablets (wafers) and were asked to take a different formulation for each of their next 2 attacks, the sequence to be at their discretion. Within similar to 24 hours after taking rizatriptan, patients were to call a toll-free number to report their responses to rizatriptan using an interactive voice-response system. Results: Within 2 hours after initial dosing of rizatriptan, significantlymore patients taking either the rizatriptan tablet or the rizatriptan wafer reported onset of pain relief, had become largely symptom free, and were able to resume usual activities compared with their baseline responses to nontriptans (P < 0.05). In addition, compared with their baseline responses to nontriptans, significantly more patients taking either rizatriptan formulation had mild or no pain 2 hours after dosing (P < 0.05). More than twiceas many patients taking the rizatriptan tablets or wafers were either somewhat or very satisfied with the medication compared with their satisfactionwith nontriptans (P < 0.05). Conclusions: In the naturalistic setting of this study, migraineurs who had not previously taken a triptan medication reported more rapid relief of pain, more effective pain relief, and more rapid resumption of normal activities when taking rizatriptan tablets or wafers than when taking a nontriptan medication. Patients dissatisfied with their current nontriptan migraine therapy may benefit from treatment with rizatriptan.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/09/20 alle ore 23:48:22